Log in
NASDAQ:AKBA

Akebia Therapeutics Stock Forecast, Price & News

$2.22
-0.05 (-2.20 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.09
Now: $2.22
$2.28
50-Day Range
$2.27
MA: $2.88
$3.78
52-Week Range
$2.09
Now: $2.22
$13.71
Volume7.41 million shs
Average Volume9.03 million shs
Market Capitalization$318.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
Akebia Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.85 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098
Employees358

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$335 million
Book Value$3.32 per share

Profitability

Net Income$-279,660,000.00
Net Margins-113.35%

Miscellaneous

Market Cap$318.17 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$2.22
-0.05 (-2.20 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

How has Akebia Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AKBA shares have decreased by 68.0% and is now trading at $2.22.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Akebia Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Akebia Therapeutics
.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Akebia Therapeutics
.

How can I listen to Akebia Therapeutics' earnings call?

Akebia Therapeutics will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.02. The biopharmaceutical company earned $90.14 million during the quarter, compared to analyst estimates of $76.24 million. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%.
View Akebia Therapeutics' earnings history
.

What price target have analysts set for AKBA?

7 analysts have issued 12-month target prices for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next year. This suggests a possible upside of 363.3% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 22,170,000 shares, an increase of 141.8% from the September 15th total of 9,170,000 shares. Based on an average daily volume of 5,120,000 shares, the short-interest ratio is currently 4.3 days.
View Akebia Therapeutics' Short Interest
.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 56, Pay $1.02M)
  • Mr. Michel Dahan, Sr. VP & COO (Age 41, Pay $567.57k)
  • Ms. Nicole R. Hadas, Sr. VP, Chief Legal Officer & Sec. (Age 47, Pay $497.37k)
  • Mr. Jason A. Amello, Exec. Officer (Age 52, Pay $578.05k)
  • Mr. Dell Faulkingham, Sr. VP & Chief Commercial Officer (Age 47, Pay $615.74k)
  • Mr. David A. Spellman, Sr. VP, CFO & Treasurer (Age 43)
  • Ms. Kristen K. Sheppard J.D., Esq., VP of Investor Relations
  • Mr. Douglas Jermasek, VP of Marketing & Strategy
  • Ms. Tamara Dillon, Sr. VP of HR
  • Dr. Karen L. Tubridy, Sr. VP & Chief Devel. Officer (Age 58)

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of New Jersey Common Pension Fund D (0.15%), DekaBank Deutsche Girozentrale (0.07%), Dupont Capital Management Corp (0.07%), Candriam Luxembourg S.C.A. (0.05%), Alpha Windward LLC (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics
.

Which institutional investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Maxine Gowen, Michel Dahan, and Nicole R Hadas.
View insider buying and selling activity for Akebia Therapeutics
.

Which institutional investors are buying Akebia Therapeutics stock?

AKBA stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Dupont Capital Management Corp, State of New Jersey Common Pension Fund D, BNP Paribas Arbitrage SA, Alpha Windward LLC, XTX Markets LLC, and Wedbush Securities Inc.. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $2.22.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $318.17 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 358 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.